Search

Your search keyword '"Coskuner, SA"' showing total 11 results
Start Over Author "Coskuner, SA" Language english
11 results on '"Coskuner, SA"'

1. patients: a multi-center study, Turkey

Author

Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, and Ormeci, N

Subjects
Chronic hepatitis B infection, Quality of life, The Hepatitis B Quality, of Life Instrument, Turkey
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

2. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Karacaer ZAUID- ORCID: 0000-0002-2658-4679, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, Ozturk C, Hasbun R, Batirel A, Yilmaz EM, Bozkurt I, Sunbul M, Aynioglu A, Atilla A, Erbay A, Inci A, Kader C, Tigen ET, Karaahmetoglu G, Coskuner SA, Dik E, Tarakci H, Tosun S, Korkmaz F, Kolgelier S, Karadag FY, Erol S, Turker K, Necan C, Sahin AM, Ergen P, Iskender G, Korkmaz P, Eroglu EG, Durdu Y, Ulug M, Deniz SS, Koc F, Alpat SN, Oztoprak N, Evirgen O, Sozen H, Dogan M, Kaya S, and Altindis M

Subjects
Adult, Aged, Antiviral Agents/therapeutic use, Cross-Sectional Studies, Female, Health Status Indicators, Hepatitis B, Chronic/drug therapy/psychology, Humans, Interviews as Topic, Male, Middle Aged, Prospective Studies, Quality of Life, Turkey
Abstract

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. METHODS: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. RESULTS: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. CONCLUSIONS: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

3. hospitals of Turkey: A multicentric study

Author

Ozgenc, O, Genc, VE, Ari, AA, Sibel, E, Sacar, S, Ozunlu, H, Akgul, A, Demirturk, N, Cetin, CB, Sungur, M, Coskuner, SA, Avci, M, and Ergonul, O

Subjects
Antibiotic restriction policy, appropriate antibiotic usage
Abstract

Purpose: The antibiotic restriction policy has been validated nationwide since February 2003 by the Ministry of Health because the excessive consumption of antimicrobials causes a high cost. The aim of this study was to evaluate the therapeutic use of antibiotics in Aegean Region hospitals and to assess the impact of this nationwide antibiotic restriction policy. This new policy is based on justification that the infectious disease (ID) physicians should be primarily responsible for the prescription of antimicrobials. Materials and Methods: Eight university and government hospitals were included in the study. The criteria of the Council for Appropriate and Rational Antibiotic Therapy (CARAT) were considered. Both patient-based and antibiotic-based analyses were performed. For the analysis of inappropriate use, logistic regression was modeled. Results: Therapeutic use was determined in 540 patients by a total of 29 ID physicians. In the study, 30.2% of the patients were given antimicrobials and empirically started antibiotics accounted for 79% cases of therapeutic antibiotic use, and 60% of those were inappropriate (P = 0.001). The appropriate use of ID level antibiotics (P = 0.000) were very compatible with other antimicrobial groups. Conclusion: The study shows that the Turkish government's new intervention policy on antimicrobial prescribing has been effective.

Published
2011

4. Managing atypical and typical herpetic central nervous system infections: results of a multinational study

Author

Signe Maj Sørensen, Jean-Paul Stahl, Seher Ayten Coskuner, Pierre Tattevin, Mauro Maresca, Sibel Bolukcu, Oğuz Reşat Sipahi, Rosa Fontana, Lykke Larsen, Xavier Argemi, Lenka Baštáková, Guillaume Béraud, Mario Poljak, Gamze Kilicoglu, Matjaž Jereb, Bruno Baršić, Akram Al-Mahdawi, Nevin Ince, Isik Somuncu Johansen, Filiz Pehlivanoglu, Sylviane Defres, Hasan Karsen, Yasemin Akkoyunlu, Asuman Inan, Souha S. Kanj, Hava Yilmaz, Nazif Elaldi, Elif Sahin-Horasan, Jesper Damsgaard Gunst, Emine Parlak, Hulya Tireli, Hakan Erdem, Anne Lisbeth Bohr, Fatime Korkmaz, Oguz Karabay, Haluk Vahaboglu, Gulden Yilmaz, Ghaydaa A. Shehata, Süheyla Kömür, Stephen L. Leib, Mahtab Chehri, Salih Atakan Nemli, Abdullah Umut Pekok, Sukran Kose, Derya Ozturk-Engin, Seniha Senbayrak, Mehmet Ulug, Gulistan Halac, Mustafa Sunbul, Gonul Sengoz, Selçuk Kaya, Ahmad Sharif-Yakan, Yasemin Cag, Institute of Microbiology and Immunology, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Fonction, structure et inactivation d'ARN bactériens, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Universitaire [Grenoble] (CHU), Cumhuriyet Universitesi, AKKOYUNLU, YASEMİN, Institute of Microbiology and Immunology - Inštitut za mikrobiologijo in imunologijo [Ljubljana, Slovenia], Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Ege Üniversitesi, [Cag, Y.] Dr Lutfi Kirdar Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Erdem, H.] Gulhane Mil Med Acad, Dept Infect Dis & Clin Microbiol, Ankara, Turkey -- [Leib, S.] Univ Bern, Inst Infect Dis, CH-3012 Bern, Switzerland -- [Defres, S.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England -- [Defres, S.] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Trop Infect Dis Unit, Liverpool, Merseyside, England -- [Kaya, S.] Karadeniz Tech Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Trabzon, Turkey -- [Larsen, L. -- Johansen, I. S.] Odense Univ Hosp, Dept Infect Dis Q, Odense, Denmark -- [Poljak, M.] Univ Ljubljana, Inst Microbiol & Immunol, Fac Med, Ljubljana, Slovenia -- [Ozturk-Engin, D. -- Bolukcu, S. -- Inan, A. -- Senbayrak, S.] Haydarpasa Numune Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Barsic, B.] Univ Zagreb, Dr Fran Mihaljev Univ Hosp Infect Dis, Dept Infect Dis, Sch Med, Zagreb, Croatia -- [Argemi, X.] Nouvel Hop Civil, Dept Infect Dis, Strasbourg, France -- [Sorensen, S. M.] Aalborg Univ Hosp, Dept Infect Dis, Aalborg, Denmark -- [Bohr, A. L.] Rigshosp, Copenhagen Univ Hosp, Inst Inflammat Res, Dept Infect Dis & Rheumatol, Copenhagen, Denmark -- [Tattevin, P.] Univ Hosp Pontchaillou, Dept Infect & Trop Dis, Rennes, France -- [Gunst, J. D.] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark -- [Bastakova, L.] Masaryk Univ, Fac Hosp Brno, Dept Infect Dis, Fac Med, Brno, Czech Republic -- [Jereb, M.] Univ Med Ctr, Dept Infect Dis, Ljubljana, Slovenia -- [Karabay, O.] Sakarya Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Sakarya, Turkey -- [Pekok, A. U.] Private Erzurum Sifa Hosp, Dept Infect Dis & Clin Microbiol, Erzurum, Turkey -- [Sipahi, O. R.] Ege Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Izmir, Turkey -- [Chehri, M.] Hvidovre Univ Hosp, Dept Infect Dis, Copenhagen, Denmark -- [Beraud, G.] Univ Poitiers Hosp, Dept Infect Dis, Poitiers, France -- [Shehata, G.] Assiut Univ Hosp, Dept Neurol & Psychiat, Assiut, Egypt -- [Fontana, R. -- Maresca, M.] Univ Catania, Infect Dis Sect, Dept Clin & Mol Biomed, Catania, Italy -- [Karsen, H.] Harran Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Sanliurfa, Turkey -- [Sengoz, G. -- Pehlivanoglu, F.] Haseki Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Sunbul, M. -- Yilmaz, H.] Ondokuz Mayis Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Samsun, Turkey -- [Yilmaz, G.] Ankara Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Ankara, Turkey -- [Sharif-Yakan, A. -- Kanj, S.] Amer Univ Beirut, Med Ctr, Beirut, Lebanon -- [Parlak, E.] Ataturk Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Erzurum, Turkey -- [Korkmaz, F.] Konya Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Konya, Turkey -- [Komur, S.] Cukurova Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Adana, Turkey -- [Kose, S.] Tepecik Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Izmir, Turkey -- [Ulug, M.] Private Umit Hosp, Dept Infect Dis & Clin Microbiol, Eskisehir, Turkey -- [Coskuner, S. A.] Izmir Bozyaka Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Izmir, Turkey -- [Stahl, J. P.] Univ Grenoble 1, Grenoble, France -- [Stahl, J. P.] Univ Hosp Grenoble, Dept Infect Dis, Grenoble, France -- [Ince, N.] Duzce Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Duzce, Turkey -- [Akkoyunlu, Y.] Bezmi Alem Vakif Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Halac, G.] Bezmi Alem Vakif Univ, Sch Med, Dept Neurol, Istanbul, Turkey -- [Sahin-Horasan, E.] Mersin Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Mersin, Turkey -- [Tireli, H.] Haydarpasa Numune Training & Res Hosp, Dept Neurol, Istanbul, Turkey -- [Kilicoglu, G.] Haydarpasa Numune Training & Res Hosp, Dept Radiol, Istanbul, Turkey -- [Al-Mahdawi, A.] Baghdad Teaching Hosp, Dept Neurol, Baghdad, Iraq -- [Nemli, S. A.] Katip Celebi Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Izmir, Turkey -- [Vahaboglu, H.] Medeniyet Univ, Goztepe Training & Res Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Elaldi, N.] Cumhuriyet Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Sivas, Turkey, Ghaydaa, Shehata -- 0000-0002-3631-893X, VAHABOGLU, Haluk -- 0000-0001-8217-1767, Kanj, Souha -- 0000-0001-6413-3396, Beraud, Guillaume -- 0000-0002-4705-0916, Gunst, Jesper -- 0000-0002-3787-0259, Stahl, Jean Paul -- 0000-0002-0086-3557, johansen, isik somuncu -- 0000-0002-2189-9823, Larsen, Lykke -- 0000-0002-4113-4182, Karabay, Oguz -- 0000-0003-0502-432X, OMÜ, Cag, Y, Erdem, H, Leib, S, Defres, S, Kaya, S, Larsen, L, Poljak, M, Ozturk-Engin, D, Barsic, B, Argemi, X, Sorensen, SM, Bohr, AL, Tattevin, P, Gunst, JD, Bastakova, L, Jereb, M, Johansen, IS, Karabay, O, Pekok, AU, Sipahi, OR, Chehri, M, Beraud, G, Shehata, G, Fontana, R, Maresca, M, Karsen, H, Sengoz, G, Sunbul, M, Yilmaz, G, Yilmaz, H, Sharif-Yakan, A, Kanj, S, Parlak, E, Pehlivanoglu, F, Korkmaz, F, Komur, S, Kose, S, Ulug, M, Bolukcu, S, Coskuner, SA, Stahl, JP, Ince, N, Akkoyunlu, Y, Halac, G, Sahin-Horasan, E, Tireli, H, Kilicoglu, G, Al-Mahdawi, A, Nemli, SA, Inan, A, Senbayrak, S, Vahaboglu, H, Elaldi, N, Sakarya Üniversitesi/İlahiyat Fakültesi/Temel İslam Bilimleri Bölümü, Kaya, Süleyman, Karabay, Oğuz, and Çukurova Üniversitesi

Subjects
Male, Pathology, [SDV]Life Sciences [q-bio], encephalitis, Electroencephalography, medicine.disease_cause, Polymerase Chain Reaction, 0302 clinical medicine, Cerebrospinal fluid, 030212 general & internal medicine, Cerebrospinal Fluid, Aged, 80 and over, medicine.diagnostic_test, Atypical presentation, Brain, meningitis, General Medicine, Middle Aged, Magnetic Resonance Imaging, 3. Good health, Infectious Diseases, medicine.anatomical_structure, results of a multinational study-, Clinical Microbiology And Infection, cilt.22, ss.568-569, 2016 [Akkoyunlu Y., Çağ Y., -Managing atypical and typical herpetic central nervous system infections], Female, Presentation (obstetrics), Encephalitis, Adult, Microbiology (medical), medicine.medical_specialty, Adolescent, Central nervous system, Microbiology, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Journal Article, Humans, Aged, Retrospective Studies, managing, Diagnostic Tests, Routine, business.industry, Magnetic resonance imaging, medicine.disease, herpes simplex virus, Herpes simplex virus, Concomitant, DNA, Viral, Encephalitis, Herpes Simplex, business, 030217 neurology & neurosurgery
Abstract

WOS: 000379252100027, PubMed ID: 27085724, There have been many studies pertaining to the management of herpetic meningoencephalitis (HME), but the majority of them have focussed on virologically unconfirmed cases or included only small sample sizes. We have conducted a multicentre study aimed at providing management strategies for HME. Overall, 501 adult patients with PCR-proven HME were included retrospectively from 35 referral centres in 10 countries; 496 patients were found to be eligible for the analysis. Cerebrospinal fluid (CSF) analysis using a PCR assay yielded herpes simplex virus (HSV)-1 DNA in 351 patients (70.8%), HSV-2 DNA in 83 patients (16.7%) and undefined HSV DNA type in 62 patients (12.5%). A total of 379 patients (76.4%) had at least one of the specified characteristics of encephalitis, and we placed these patients into the encephalitis presentation group. The remaining 117 patients (23.6%) had none of these findings, and these patients were placed in the nonencephalitis presentation group. Abnormalities suggestive of encephalitis were detected in magnetic resonance imaging (MRI) in 83.9% of the patients and in electroencephalography (EEG) in 91.0% of patients in the encephalitis presentation group. In the nonencephalitis presentation group, MRI and EEG data were suggestive of encephalitis in 33.3 and 61.9% of patients, respectively. However, the concomitant use of MRI and EEG indicated encephalitis in 96.3 and 87.5% of the cases with and without encephalitic clinical presentation, respectively. Considering the subtle nature of HME, CSF HSV PCR, EEG and MRI data should be collected for all patients with a central nervous system infection. (C) 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Published
2016
Full Text
View/download PDF

5. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Author

Ayse Inci, Fatma Yılmaz Karadağ, Pınar Ergen, Saygin Nayman Alpat, Rezan Harman, Ilhami Celik, Filiz Koc, Hakan Erdem, Mehmet Bitirgen, Ilknur Yavuz, Nefise Oztoprak, Ayse Batirel, Banu Cakir, Mustafa Namiduru, Esmeray Mutlu Yilmaz, Kevser Ozdemir, Emsal Aydin, Yasemin Durdu, Kenan Ugurlu, Nevin Ince, Aynur Atilla, Büşra Ergüt Sezer, Emel Aslan, Serpil Erol, Mustafa Hatipoglu, Hatice Udurgucu, Mustafa Sunbul, Ayşe Erbay, Ercan Yenilmez, Hacer Deniz Ozkaya, Yeşim Alpay, Esma Gulesen Eroglu, Mehmet Faruk Geyik, Emine Parlak, Hüseyin Tarakçı, Rodrigo Hasbun, Gunes Senol, Aynur Aynioglu, Ilkay Bozkurt, Necati Örmeci, Recep Tekin, Seher Ayten Coskuner, Gokhan Karaahmetoglu, Ebru Dik, Zehra Karacaer, Suna Seçil Öztürk Deniz, Gulsen Iskender, Selma Tosun, Fatime Korkmaz, Ilker Inanc Balkan, Ergenekon Karagoz, Fatma Sirmatel, Suzan Sacar, Ömer Evirgen, Mustafa Dogan, Ayten Kadanali, Senol Comoglu, Rahmet Guner, Ahmet Şahin, Affan Denk, Elif Tukenmez Tigen, Ceyda Necan, Aliye Bastug, Ahmet Sahin, Cinar Ozturk, Hamdi Sözen, Çiğdem Kader, Mustafa Altindiş, Şafak Kaya, Selçuk Kaya, Mehmet Ulug, Servet Kolgelier, Gül Durmuş, Kamuran Turker, Ahmet Karakaş, Gülden Ersöz, Pinar Korkmaz, Rukiye Pinar Bölüktaş, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı, Şahin, Ahmet Melih, Karacaer, Zehra, Cakir, Banu, Erdem, Hakan, Ugurlu, Kenan, Durmus, Gul, Ince, Nevin Koc, Ozturk, Cinar, Hasbun, Rodrigo, Batirel, Ayse, Yilmaz, Esmeray Mutlu, Bozkurt, Ilkay, Sunbul, Mustafa, Aynioglu, Aynur, Atilla, Aynur, Erbay, Ayse, Inci, Ayse, Kader, Cigdem, Tigen, Elif Tukenmez, Karaahmetoglu, Gokhan, Coskuner, Seher Ayten, Dik, Ebru, Tarakci, Huseyin, Tosun, Selma, Korkmaz, Fatime, Kolgelier, Servet, Karadag, Fatma Yilmaz, Erol, Serpil, Turker, Kamuran, Necan, Ceyda, Sahin, Ahmet Melih, Ergen, Pinar, Iskender, Gulsen, Korkmaz, Pinar, Eroglu, Esma Gulesen, Durdu, Yasemin, Ulug, Mehmet, Deniz, Suna Secil, Koc, Filiz, Alpat, Saygin Nayman, Oztoprak, Nefise, Evirgen, Omer, Sozen, Hamdi, Dogan, Mustafa, Kaya, Selcuk, Kaya, Safak, Altindis, Mustafa, Aslan, Emel, Tekin, Recep, Sezer, Busra Ergut, Ozdemir, Kevser, Ersoz, Gulden, Sahin, Ahmet, Celik, Ilhami, Aydin, Emsal, Bastug, Aliye, Harman, Rezan, Ozkaya, Hacer Deniz, Parlak, Emine, Yavuz, Ilknur, Sacar, Suzan, Comoglu, Senol, Yenilmez, Ercan, Sirmatel, Fatma, Balkan, Ilker Inanc, Alpay, Yesim, Hatipoglu, Mustafa, Denk, Affan, Senol, Gunes, Bitirgen, Mehmet, Geyik, Mehmet Faruk, Guner, Rahmet, Kadanali, Ayten, Karakas, Ahmet, Namiduru, Mustafa, Udurgucu, Hatice, Boluktas, Rukiye Pinar, Karagoz, Ergenekon, Ormeci, Necati, Karacaer, Z, Cakir, B, Erdem, H, Ugurlu, K, Durmus, G, Ince, NK, Ozturk, C, Hasbun, R, Batirel, A, Yilmaz, EM, Bozkurt, I, Sunbul, M, Aynioglu, A, Atilla, A, Erbay, A, Inci, A, Kader, C, Tigen, ET, Karaahmetoglu, G, Coskuner, SA, Dik, E, Tarakci, H, Tosun, S, Korkmaz, F, Kolgelier, S, Karadag, FY, Erol, S, Turker, K, Necan, C, Sahin, AM, Ergen, P, Iskender, G, Korkmaz, P, Eroglu, EG, Durdu, Y, Ulug, M, Deniz, SS, Koc, F, Alpat, SN, Oztoprak, N, Evirgen, O, Sozen, H, Dogan, M, Kaya, S, Altindis, M, Aslan, E, Tekin, R, Sezer, BE, Ozdemir, K, Ersoz, G, Sahin, A, Celik, I, Aydin, E, Bastug, A, Harman, R, Ozkaya, HD, Parlak, E, Yavuz, I, Sacar, S, Comoglu, S, Yenilmez, E, Sirmatel, F, Balkan, II, Alpay, Y, Hatipoglu, M, Denk, A, Senol, G, Bitirgen, M, Geyik, MF, Guner, R, Kadanali, A, Karakas, A, Namiduru, M, Udurgucu, H, Boluktas, RP, Karagoz, E, Ormeci, N, Sakarya Üniversitesi/Tıp Fakültesi/Temel Tıp Bilimleri Bölümü, Altındiş, Mustafa, Tıp Fakültesi, RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Öztürk, Çınar, MÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sözen, Hamdi, Zonguldak Bülent Ecevit Üniversitesi, Halk Sağlığı, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Sırmatel, Fatma, and OMÜ

Subjects
antivirus agent, Male, demography, MARITAL-STATUS, Turkey, Cross-sectional study, IMPACT, Disease, DETERMINANTS, Turkey (republic), 0302 clinical medicine, Quality of life, antiviral therapy, Health Status Indicators, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, The Hepatitis B Quality of Life Instrument, food and beverages, clinical trial, General Medicine, Middle Aged, Hepatitis B, humanities, Chronic hepatitis B infection, Female, 030211 gastroenterology & hepatology, HEALTH, prospective study, Adult, medicine.medical_specialty, Chronic Hepatitis B Infection, quality of life assessment, psychology, Antiviral Agents, Article, Interviews as Topic, 03 medical and health sciences, Hepatitis B, Chronic, Chronic hepatitis, UTILITIES, Internal medicine, medicine, cross-sectional study, Humans, chronic hepatitis B, controlled study, human, Aged, Related factors, business.industry, Research, fungi, Public Health, Environmental and Occupational Health, Hepatitis B Quality of Life, interview, medicine.disease, major clinical study, COMORBIDITIES, hepatitis B surface antigen, multicenter study, Cross-Sectional Studies, Health Care Sciences & Services, Short Form 36, Multi center study, Physical therapy, Quality of Life, business, health status indicator
Abstract

WOS: 000386954300001, PubMed: 27809934, Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016

6. Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis

Author

Pierre Tattevin, Salih Atakan Nemli, Hasan Karsen, Mustafa Sunbul, Rosa Fontana Del Vecchio, Akram Al-Mahdawi, Mahtab Chehri, Süheyla Kömür, Sylviane Defres, Bruno Baršić, Signe Maj Sørensen, Seniha Senbayrak, Ghaydaa A. Shehata, Nevin Ince, Abdullah Umut Pekok, Selçuk Kaya, Yasemin Akkoyunlu, Gulden Yilmaz, Jean-Paul Stahl, Lykke Larsen, Lenka Baštáková, Gonul Sengoz, Jesper Damsgaard Gunst, Guillaume Béraud, Emine Parlak, Hakan Erdem, Sukran Kose, Oğuz Reşat Sipahi, Hava Yilmaz, Filiz Pehlivanoglu, Xavier Argemi, Asuman Inan, Hulya Tireli, Haluk Vahaboglu, Elif Sahin-Horasan, Souha S. Kanj, Gamze Kilicoglu, Fatime Korkmaz, Anne Lisbeth Bohr, Oguz Karabay, Mehmet Ulug, Gulistan Halac, Derya Ozturk-Engin, Seher Ayten Coskuner, Mario Poljak, Mauro Maresca, Sibel Bolukcu, Ahmad Sharif-Yakan, Yasemin Cag, Isik Somuncu Johansen, Matjaž Jereb, Ege Üniversitesi, AKKOYUNLU, YASEMİN, Erdem, H, Cag, Y, Ozturk-Engin, D, Defres, S, Kaya, S, Larsen, L, Poljak, M, Barsic, B, Argemi, X, Sorensen, SM, Bohr, AL, Tattevin, P, Gunst, JD, Bastakova, L, Jereb, M, Johansen, IS, Karabay, O, Pekok, AU, Sipahi, OR, Chehri, M, Beraud, G, Shehata, G, Del Vecchio, RF, Maresca, M, Karsen, H, Sengoz, G, Sunbul, M, Yilmaz, G, Yilmaz, H, Sharif-Yakan, A, Kanj, SS, Parlak, E, Pehlivanoglu, F, Korkmaz, F, Komur, S, Kose, S, Ulug, M, Bolukcu, S, Coskuner, SA, Ince, N, Akkoyunlu, Y, Halac, G, Sahin-Horasan, E, Tireli, H, Kilicoglu, G, Al-Mandawi, A, Nemli, SA, Inan, A, Senbayrak, S, Stahl, JP, Vahaboglu, H, Sakarya Üniversitesi/İlahiyat Fakültesi/Temel İslam Bilimleri Bölümü, Kaya, Süleyman, Karabay, Oğuz, Çukurova Üniversitesi, and OMÜ

Subjects
Adult, Male, medicine.medical_specialty, Referral, Antiviral Agents, Internal medicine, medicine, ERDEM H., CAG Y., OZTURK-ENGIN D., Defres S., KAYA S., LARSEN L., POLJAK M., BARSIC B., ARGEMI X., SORENSEN S. M. , et al., -Results of a Multinational Study Suggest the Need for Rapid Diagnosis and Early Antiviral Treatment at the Onset of Herpetic Meningoencephalitis-, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, cilt.59, ss.3084-3089, 2015, Confidence Intervals, Humans, Pharmacology (medical), Pharmacology & Pharmacy, Antiviral treatment, Retrospective Studies, Pharmacology, business.industry, Herpetic meningoencephalitis, Glasgow Coma Scale, Retrospective cohort study, Odds ratio, Middle Aged, medicine.disease, Confidence interval, 3. Good health, Surgery, Infectious Diseases, Treatment Outcome, Female, Encephalitis, Herpes Simplex, business, Encephalitis
Abstract

WOS: 000358623200015, PubMed ID: 25779579, Data in the literature regarding the factors that predict unfavorable outcomes in adult herpetic meningoencephalitis (HME) cases are scarce. We conducted a multicenter study in order to provide insights into the predictors of HME outcomes, with special emphasis on the use and timing of antiviral treatment. Samples from 501 patients with molecular confirmation from cerebrospinal fluid were included from 35 referral centers in 10 countries. Four hundred thirty-eight patients were found to be eligible for the analysis. Overall, 232 (52.9%) patients experienced unfavorable outcomes, 44 died, and 188 survived, with sequelae. Age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02 to 1.05), Glasgow Coma Scale score (OR, 0.84; 95% CI, 0.77 to 0.93), and symptomatic periods of 2 to 7 days (OR, 1.80; 95% CI, 1.16 to 2.79) and >7 days (OR, 3.75; 95% CI, 1.72 to 8.15) until the commencement of treatment predicted unfavorable outcomes. The outcome in HME patients is related to a combination of therapeutic and host factors. This study suggests that rapid diagnosis and early administration of antiviral treatment in HME patients are keys to a favorable outcome.

Published
2015
Full Text
View/download PDF

7. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey.

Author

Karacaer Z, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, Ozturk C, Hasbun R, Batirel A, Yilmaz EM, Bozkurt I, Sunbul M, Aynioglu A, Atilla A, Erbay A, Inci A, Kader C, Tigen ET, Karaahmetoglu G, Coskuner SA, Dik E, Tarakci H, Tosun S, Korkmaz F, Kolgelier S, Karadag FY, Erol S, Turker K, Necan C, Sahin AM, Ergen P, Iskender G, Korkmaz P, Eroglu EG, Durdu Y, Ulug M, Deniz SS, Koc F, Alpat SN, Oztoprak N, Evirgen O, Sozen H, Dogan M, Kaya S, Kaya S, Altindis M, Aslan E, Tekin R, Sezer BE, Ozdemir K, Ersoz G, Sahin A, Celik I, Aydin E, Bastug A, Harman R, Ozkaya HD, Parlak E, Yavuz I, Sacar S, Comoglu S, Yenilmez E, Sirmatel F, Balkan II, Alpay Y, Hatipoglu M, Denk A, Senol G, Bitirgen M, Geyik MF, Guner R, Kadanali A, Karakas A, Namiduru M, Udurgucu H, Boluktas RP, Karagoz E, and Ormeci N

Subjects
Adult, Aged, Antiviral Agents therapeutic use, Cross-Sectional Studies, Female, Health Status Indicators, Humans, Interviews as Topic, Male, Middle Aged, Prospective Studies, Turkey, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic psychology, Quality of Life
Abstract

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors., Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant., Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided., Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

Published
2016
Full Text
View/download PDF

8. Managing atypical and typical herpetic central nervous system infections: results of a multinational study.

Author

Cag Y, Erdem H, Leib S, Defres S, Kaya S, Larsen L, Poljak M, Ozturk-Engin D, Barsic B, Argemi X, Sørensen SM, Bohr AL, Tattevin P, Gunst JD, Baštáková L, Jereb M, Johansen IS, Karabay O, Pekok AU, Sipahi OR, Chehri M, Beraud G, Shehata G, Fontana R, Maresca M, Karsen H, Sengoz G, Sunbul M, Yilmaz G, Yilmaz H, Sharif-Yakan A, Kanj S, Parlak E, Pehlivanoglu F, Korkmaz F, Komur S, Kose S, Ulug M, Bolukcu S, Coskuner SA, Stahl JP, Ince N, Akkoyunlu Y, Halac G, Sahin-Horasan E, Tireli H, Kilicoglu G, Al-Mahdawi A, Nemli SA, Inan A, Senbayrak S, Vahaboglu H, and Elaldi N

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Brain diagnostic imaging, Cerebrospinal Fluid virology, DNA, Viral analysis, DNA, Viral genetics, Diagnostic Tests, Routine, Electroencephalography, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Polymerase Chain Reaction, Retrospective Studies, Young Adult, Encephalitis, Herpes Simplex diagnosis, Encephalitis, Herpes Simplex therapy
Abstract

There have been many studies pertaining to the management of herpetic meningoencephalitis (HME), but the majority of them have focussed on virologically unconfirmed cases or included only small sample sizes. We have conducted a multicentre study aimed at providing management strategies for HME. Overall, 501 adult patients with PCR-proven HME were included retrospectively from 35 referral centres in 10 countries; 496 patients were found to be eligible for the analysis. Cerebrospinal fluid (CSF) analysis using a PCR assay yielded herpes simplex virus (HSV)-1 DNA in 351 patients (70.8%), HSV-2 DNA in 83 patients (16.7%) and undefined HSV DNA type in 62 patients (12.5%). A total of 379 patients (76.4%) had at least one of the specified characteristics of encephalitis, and we placed these patients into the encephalitis presentation group. The remaining 117 patients (23.6%) had none of these findings, and these patients were placed in the nonencephalitis presentation group. Abnormalities suggestive of encephalitis were detected in magnetic resonance imaging (MRI) in 83.9% of the patients and in electroencephalography (EEG) in 91.0% of patients in the encephalitis presentation group. In the nonencephalitis presentation group, MRI and EEG data were suggestive of encephalitis in 33.3 and 61.9% of patients, respectively. However, the concomitant use of MRI and EEG indicated encephalitis in 96.3 and 87.5% of the cases with and without encephalitic clinical presentation, respectively. Considering the subtle nature of HME, CSF HSV PCR, EEG and MRI data should be collected for all patients with a central nervous system infection., (Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)

Published
2016
Full Text
View/download PDF

9. Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis.

Author

Erdem H, Cag Y, Ozturk-Engin D, Defres S, Kaya S, Larsen L, Poljak M, Barsic B, Argemi X, Sørensen SM, Bohr AL, Tattevin P, Gunst JD, Baštáková L, Jereb M, Johansen IS, Karabay O, Pekok AU, Sipahi OR, Chehri M, Beraud G, Shehata G, Del Vecchio RF, Maresca M, Karsen H, Sengoz G, Sunbul M, Yilmaz G, Yilmaz H, Sharif-Yakan A, Kanj SS, Parlak E, Pehlivanoglu F, Korkmaz F, Komur S, Kose S, Ulug M, Bolukcu S, Coskuner SA, Ince N, Akkoyunlu Y, Halac G, Sahin-Horasan E, Tireli H, Kilicoglu G, Al-Mahdawi A, Nemli SA, Inan A, Senbayrak S, Stahl JP, and Vahaboglu H

Subjects
Adult, Confidence Intervals, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Antiviral Agents therapeutic use, Encephalitis, Herpes Simplex diagnosis, Encephalitis, Herpes Simplex drug therapy
Abstract

Data in the literature regarding the factors that predict unfavorable outcomes in adult herpetic meningoencephalitis (HME) cases are scarce. We conducted a multicenter study in order to provide insights into the predictors of HME outcomes, with special emphasis on the use and timing of antiviral treatment. Samples from 501 patients with molecular confirmation from cerebrospinal fluid were included from 35 referral centers in 10 countries. Four hundred thirty-eight patients were found to be eligible for the analysis. Overall, 232 (52.9%) patients experienced unfavorable outcomes, 44 died, and 188 survived, with sequelae. Age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02 to 1.05), Glasgow Coma Scale score (OR, 0.84; 95% CI, 0.77 to 0.93), and symptomatic periods of 2 to 7 days (OR, 1.80; 95% CI, 1.16 to 2.79) and >7 days (OR, 3.75; 95% CI, 1.72 to 8.15) until the commencement of treatment predicted unfavorable outcomes. The outcome in HME patients is related to a combination of therapeutic and host factors. This study suggests that rapid diagnosis and early administration of antiviral treatment in HME patients are keys to a favorable outcome., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)

Published
2015
Full Text
View/download PDF

10. Clinical, diagnostic and therapeutic approaches to complications of brucellosis: an experience of 12 years.

Author

Mermut G, Ozgenç O, Avcı M, Olut AI, Oktem E, Genç VE, Arı A, and Coskuner SA

Subjects
Adolescent, Adult, Aged, Blood Sedimentation, Brucellosis diagnosis, C-Reactive Protein metabolism, Diagnosis, Differential, Doxycycline therapeutic use, Female, Gastrointestinal Diseases diagnosis, Gastrointestinal Diseases epidemiology, Gastrointestinal Diseases microbiology, Hematologic Diseases diagnosis, Hematologic Diseases epidemiology, Hematologic Diseases microbiology, Humans, Joint Diseases diagnosis, Joint Diseases epidemiology, Joint Diseases microbiology, Male, Middle Aged, Prevalence, Retrospective Studies, Rifampin therapeutic use, Streptomycin therapeutic use, Time Factors, Turkey, Young Adult, Anti-Bacterial Agents therapeutic use, Brucellosis complications, Brucellosis drug therapy, Gastrointestinal Diseases drug therapy, Hematologic Diseases drug therapy, Joint Diseases drug therapy
Abstract

Objective: To describe the clinical presentations, laboratory findings, prevalence and pattern of complications and the response to treatment of brucellosis in a 12-year period in a Turkish research hospital., Materials and Methods: Between 1996 and 2008, 231 patients were diagnosed with brucellosis and treated in our clinic. Medical records of 189 of the 231 patients with at least one demonstrable complication of the disease were reviewed for anamnesis, diagnosis, complications, treatment and clinical outcomes., Results: The decreasing order of the complications was: hematological, 104 (55%); osteoarticular, 70 (37%); hepatobiliary, 59 (31%), and gastrointestinal, 23 (12%). The most common laboratory findings were anemia, lymphomonocytosis, elevated sedimentation rate and C-reactive protein, and elevated aminotransaminases., Conclusion: The hematological, osteoarticular and hepatobiliary manifestations were predominant. Bursitis, synovitis, glomerulonephritis, cutaneous lesion and deep vein thrombosis were the rare complications observed in our study. In clinical practice, brucellosis should be considered in the differential diagnosis in the presence of infrequent complications., (Copyright © 2011 S. Karger AG, Basel.)

Published
2012
Full Text
View/download PDF

11. Hospital acquired infections (HAI) in the elderly: comparison with the younger patients.

Author

Avci M, Ozgenc O, Coskuner SA, and Olut AI

Subjects
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Cross Infection microbiology, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Turkey, Young Adult, Cross Infection epidemiology
Abstract

The aim of this retrospective study is to determine the frequency, type, microbiological characteristics and outcome of HAIs in the elderly (age ≥ 65) and to compare the data with younger patients in a Turkish Training and Research Hospital. From January 2008 to December 2009, the infection control team analyzed HAIs among 60,585 hospitalized patients (20,109 aged ≥ 65 and 40,747 aged between 18 and 64 years) with a total number of 419,017 patient days. A total of 825 HAIs episodes were detected in 607 patients, of which 395 episodes were in 301 elderly patients. The incidence of HAIs per 1000 patient days was 2.49 in the elderly and 1.64 in the younger patients' group (p<0.001). The most common site of infection in the elderly patients was the urinary tract, whereas in non-elderly group this was the lower respiratory tract. The incidence density of urinary tract infections, respiratory tract infections, surgical site, skin and soft tissue infections, primary bacteremia, and prosthesis infections were significantly higher in the elderly group (p<0.05). Gram-negative species were the most frequently isolated agents in both groups. There were no significant differences between the groups in the frequency of isolated pathogens or antibiotic susceptibility patterns. Overall, the fatality rate was found 16.8%. The elderly patients were more likely to have crude mortality rates (22% vs. 12%; p<0.01). The death was most often related to pneumonia, primary bacteremia or intravascular catheter infections in both groups., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results